- Home
- WLGS vs KLTO Comparison
WLGS vs KLTO Comparison
Compare WLGS & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- KLTO
- Stock Information
- Founded
- WLGS 1981
- KLTO 2019
- Country
- WLGS Hong Kong
- KLTO United States
- Employees
- WLGS N/A
- KLTO N/A
- Industry
- WLGS Engineering & Construction
- KLTO
- Sector
- WLGS Consumer Discretionary
- KLTO
- Exchange
- WLGS Nasdaq
- KLTO NYSE
- Market Cap
- WLGS 4.7M
- KLTO 5.0M
- IPO Year
- WLGS 2023
- KLTO N/A
- Fundamental
- Price
- WLGS $0.21
- KLTO $0.16
- Analyst Decision
- WLGS
- KLTO
- Analyst Count
- WLGS 0
- KLTO 0
- Target Price
- WLGS N/A
- KLTO N/A
- AVG Volume (30 Days)
- WLGS 3.3M
- KLTO 152.3K
- Earning Date
- WLGS 05-06-2025
- KLTO 05-15-2025
- Dividend Yield
- WLGS N/A
- KLTO N/A
- EPS Growth
- WLGS N/A
- KLTO N/A
- EPS
- WLGS 0.02
- KLTO N/A
- Revenue
- WLGS $7,272,879.00
- KLTO N/A
- Revenue This Year
- WLGS N/A
- KLTO N/A
- Revenue Next Year
- WLGS N/A
- KLTO N/A
- P/E Ratio
- WLGS $10.64
- KLTO N/A
- Revenue Growth
- WLGS 66.93
- KLTO N/A
- 52 Week Low
- WLGS $0.20
- KLTO $0.11
- 52 Week High
- WLGS $9.66
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- WLGS 28.21
- KLTO N/A
- Support Level
- WLGS $0.16
- KLTO N/A
- Resistance Level
- WLGS $0.20
- KLTO N/A
- Average True Range (ATR)
- WLGS 0.03
- KLTO 0.00
- MACD
- WLGS 0.18
- KLTO 0.00
- Stochastic Oscillator
- WLGS 38.11
- KLTO 0.00
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.